-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Aerovate Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q2 2024.
- Aerovate Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $3.87M, a 27.4% increase year-over-year.
- Aerovate Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $14.6M, a 68.3% increase year-over-year.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11.9M, a 117% increase from 2022.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5.48M, a 168% increase from 2021.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.04M, a 3422% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)